Salmecort, aerosol 25 mcg+250 mcg/dose 120 doses

Salmecort is a combined bronchodilator (contains salmoterol and fluticasone propionate). Salmeterol is a selective agonist of beta2-adrenoreceptors of prolonged action (at least 12 hours). Salmeterol molecule has a long side chain that binds to the outer domain of the receptor.

Due to these pharmacological properties, salmeterol is more effective to prevent histamine-induced bronchospasm and causes more prolonged bronchodilation compared to conventional short acting beta2-receptor agonists. Effectively and long-lasting inhibits the release of mast cell mediators such as histamine, leukotrienes, and PgD2 in the lung tissue. It suppresses early and late stage of allergic reaction; after a single dose bronchial hyperresponsiveness decreases, inhibition of late stage persists for more than 30 hours after a single dose when bronchodilator effect is absent.

Fluticasone propionate – GCS of local action. When administered by inhalation in recommended doses it has a marked anti-inflammatory and anti-allergic effect that leads to reduction of symptoms and decreases the frequency of exacerbations of diseases accompanied by airway obstruction.

Long-term use of inhaled fluticasone propionate at maximum doses daily and reserve secretion of adrenal hormones remains within normal limits in adults and children. A residual decrease in reserve adrenal function may persist for a long time after therapy.

Indications

Active ingredient

Composition

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities